Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

NEXT STORY
Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
PREV STORY
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia

author_avatar
NASDAQ Market News

Revolo Biotherapeutics to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium

author_avatar
NASDAQ Market News

AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

author_avatar
NASDAQ Market News